Halozyme Therapeutics (HALO) Treasury Shares (2010 - 2025)

Halozyme Therapeutics (HALO) has 16 years of Treasury Shares data on file, last reported at $1.5 million in Q4 2025.

• Treasury Shares for Q4 2025 came in at $1.5 million, up 8.8% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.5 million (up 8.8% YoY), and the FY2025 annual result was $1.5 million, up 8.8% from the prior year.
• Treasury Shares improved to $1.5 million in Q4 2025 per HALO's latest filing, from $1.4 million in the prior quarter.
• Over five years, Treasury Shares peaked at $19.1 million in Q2 2024 and troughed at $1.0 million in Q2 2021.
• A 5-year average of $5.2 million and a median of $4.0 million in 2021 frame the typical range for Treasury Shares.
• The sharpest annual moves came in 2021 and 2023: Treasury Shares surged 1074.93% in 2021, then tumbled 74.68% in 2023.
• A 5-year view of Treasury Shares shows it stood at $3.9 million in 2021, then increased by 15.38% to $4.5 million in 2022, then plunged by 74.68% to $1.1 million in 2023, then gained by 22.77% to $1.4 million in 2024, then advanced by 8.8% to $1.5 million in 2025.
• Business Quant data shows HALO's Treasury Shares at $1.5 million in Q4 2025, $1.4 million in Q4 2024, and $19.1 million in Q2 2024.